Agnieszka Boesen

Array ( [id] => 18013553 [patent_doc_number] => 11505837 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-22 [patent_title] => Method for evaluation of viability of viruses with lymphotropism properties [patent_app_type] => utility [patent_app_number] => 17/157335 [patent_app_country] => US [patent_app_date] => 2021-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5007 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17157335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16807863 [patent_doc_number] => 20210130416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => METHODS OF OPTIMIZING NUCLEOTIDE SEQUENCES ENCODING ENGINEERED INFLUENZA PROTEINS [patent_app_type] => utility [patent_app_number] => 17/147137 [patent_app_country] => US [patent_app_date] => 2021-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25342 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17147137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17769386 [patent_doc_number] => 11401314 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => T-cell modulatory multimeric polypeptides and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/131104 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 82 [patent_no_of_words] => 69308 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17131104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18244060 [patent_doc_number] => 20230076371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => PHARMACEUTICAL COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/784086 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17784086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537496 [patent_doc_number] => 20230242590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => TREATMENT OF DISEASES RELATED TO HEPATITIS B VIRUS [patent_app_type] => utility [patent_app_number] => 17/779564 [patent_app_country] => US [patent_app_date] => 2020-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537496 [patent_doc_number] => 20230242590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => TREATMENT OF DISEASES RELATED TO HEPATITIS B VIRUS [patent_app_type] => utility [patent_app_number] => 17/779564 [patent_app_country] => US [patent_app_date] => 2020-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537496 [patent_doc_number] => 20230242590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => TREATMENT OF DISEASES RELATED TO HEPATITIS B VIRUS [patent_app_type] => utility [patent_app_number] => 17/779564 [patent_app_country] => US [patent_app_date] => 2020-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19258006 [patent_doc_number] => 12018049 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Compositions and related methods for controlling vector-borne diseases [patent_app_type] => utility [patent_app_number] => 17/109851 [patent_app_country] => US [patent_app_date] => 2020-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 68 [patent_figures_cnt] => 85 [patent_no_of_words] => 65905 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17109851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885387 [patent_doc_number] => 20210171582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => METHOD FOR ROBUST CONTROL OF GENE EXPRESSION [patent_app_type] => utility [patent_app_number] => 17/100857 [patent_app_country] => US [patent_app_date] => 2020-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17100857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449646 [patent_doc_number] => 20230190922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer [patent_app_type] => utility [patent_app_number] => 17/778374 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449646 [patent_doc_number] => 20230190922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer [patent_app_type] => utility [patent_app_number] => 17/778374 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16686842 [patent_doc_number] => 20210069317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS [patent_app_type] => utility [patent_app_number] => 16/952864 [patent_app_country] => US [patent_app_date] => 2020-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16952864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621551 [patent_doc_number] => 20210040204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => Humanized Anti-Claudin-1 Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/081124 [patent_app_country] => US [patent_app_date] => 2020-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17081124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18034602 [patent_doc_number] => 20220378817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => SYNTHETIC RIG-I-LIKE RECEPTOR AGONISTS [patent_app_type] => utility [patent_app_number] => 17/770881 [patent_app_country] => US [patent_app_date] => 2020-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61248 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -214 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17770881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18034602 [patent_doc_number] => 20220378817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => SYNTHETIC RIG-I-LIKE RECEPTOR AGONISTS [patent_app_type] => utility [patent_app_number] => 17/770881 [patent_app_country] => US [patent_app_date] => 2020-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61248 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -214 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17770881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17621182 [patent_doc_number] => 11340230 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-24 [patent_title] => Subject anti-HCV antibody detection assays employing NS3 capture peptides [patent_app_type] => utility [patent_app_number] => 17/071976 [patent_app_country] => US [patent_app_date] => 2020-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 17 [patent_no_of_words] => 19518 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 211 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868539 [patent_doc_number] => 20210162006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => Use of CD24 Proteins for Treating Leptin-Deficient Conditions [patent_app_type] => utility [patent_app_number] => 17/067929 [patent_app_country] => US [patent_app_date] => 2020-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5993 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17067929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18335315 [patent_doc_number] => 20230127263 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => MODIFIED T CELLS AND METHODS OF PREPARING THE SAME [patent_app_type] => utility [patent_app_number] => 17/762360 [patent_app_country] => US [patent_app_date] => 2020-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18956 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17762360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18230718 [patent_doc_number] => 20230069712 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => COMPOUNDS FOR THE INDUCTION OF ANTIGEN-SPECIFIC IMMUNE TOLERANCE [patent_app_type] => utility [patent_app_number] => 17/753603 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753603 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18003600 [patent_doc_number] => 20220362366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => HUMAN ANTI-PD-L1 PEPTIDE VACCINES AND METHODS OF THEIR USE [patent_app_type] => utility [patent_app_number] => 17/761457 [patent_app_country] => US [patent_app_date] => 2020-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33726 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17761457 [rel_patent_id] =>[rel_patent_doc_number] =>)